NASDAQ: AMRN · Life Sciences · 2 alerts · CIK 897448
Share price
$11.31Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Amarin Corp Plc\Uk filings on SEC EDGAR ↗
Amarin Corporation plc reported a net income of $0.2 million for the third quarter of 2026, a significant improvement from a $7.7 million loss in the prior year period. Total revenue decreased to $39.6 million from $49.7 million year-over-year, primarily due to lower product revenue, though the company successfully reduced operating expenses by approximately 44%.
Amarin Corporation reported Q3 2026 financial results, achieving positive net income of $0.2 million and a 44% reduction in operating expenses. The company highlighted strong international momentum with a 68% increase in European in-market demand for VAZKEPA and maintained a 47% share of the U.S. icosapent ethyl market.
“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value.”